Noveome Biotherapeutics
Clinical-stage biotherapeutics company developing non-cell-based regenerative therapies using its proprietary secretome-based platform for treating degenerative diseases and injuries.
Website
https://www.noveome.comLocation
Pittsburgh, Pennsylvania, USA
Founded
2006
Investors
1
Categories
biotech, regenerative-medicine, cell-therapy, ophthalmology
Notes
Noveome Biotherapeutics is a clinical-stage company developing regenerative therapies using its proprietary secretome-based technology. The company's platform leverages the therapeutic factors secreted by cells (the secretome) without requiring cell transplantation.
Noveome's lead programs focus on ophthalmology and wound healing applications, where the regenerative properties of the secretome can promote tissue repair and healing.
Team
- David Weinstein - Chief Executive Officer
Additional Research Findings
- Founded in 2006 in Pittsburgh, Pennsylvania
- Portfolio company of Abingworth
- Proprietary secretome-based therapeutic platform
- Focus on regenerative medicine without cell transplantation
- Lead programs in ophthalmology and wound healing
- Secretome approach offers advantages over traditional cell therapy
- University of Pittsburgh spin-out
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Abingworth | London, UK / Boston, USA | biotech-focused | seedseries-a+3 | 34 |